Further probes were selected to detect ALK mutations or amplifications [19,20,45], focusing on the most common druggable mutations present in neuroblastoma, and genes involved in the p53/MDM2- and Ras/MAPK-pathway, as mutations of these genes have been previously shown to define a group of UHR neuroblastomas [13]. The gene discussed is TP53; the disease is neuroblastoma.